HC Wainwright & Co. Initiates Coverage On Anebulo Pharmaceuticals with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Anebulo Pharmaceuticals with a Buy rating and sets a price target of $6.
September 18, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anebulo Pharmaceuticals receives a Buy rating from HC Wainwright & Co. with a price target of $6.
The Buy rating and price target set by HC Wainwright & Co. indicates a positive outlook for Anebulo Pharmaceuticals. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100